{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:23:49Z","timestamp":1776183829449,"version":"3.50.1"},"reference-count":9,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,14]]},"DOI":"10.1182\/bloodadvances.2026019629","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:31:25Z","timestamp":1776180685000},"page":"2549-2550","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Monovalent antibody treatment of von Willebrand disease"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0309-3313","authenticated-orcid":false,"given":"James S.","family":"O\u2019Donnell","sequence":"first","affiliation":[{"name":"Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"7","key":"2026041411311956500_bib1","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1182\/bloodadvances.2025018516","article-title":"HMB-002: a monovalent antibody that elevates circulating VWF and FVIII levels for treatment of von Willebrand disease","volume":"10","author":"H\u00e4ger","year":"2026","journal-title":"Blood Adv"},{"issue":"1","key":"2026041411311956500_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41572-024-00536-8","article-title":"von Willebrand disease","volume":"10","author":"Seidizadeh","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"21","key":"2026041411311956500_bib3","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"von Willebrand's Disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N Engl J Med"},{"issue":"17","key":"2026041411311956500_bib4","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1182\/blood.2020008501","article-title":"von Willebrand disease: what does the future hold?","volume":"137","author":"Denis","year":"2021","journal-title":"Blood"},{"issue":"18","key":"2026041411311956500_bib5","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1182\/bloodadvances.2022007805","article-title":"The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF\/FVIII in type 2B von Willebrand disease","volume":"6","author":"Ay","year":"2022","journal-title":"Blood Adv"},{"issue":"21","key":"2026041411311956500_bib6","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1182\/blood.2025029401","article-title":"A bispecific nanobody for the treatment of von Willebrand disease-type 1","volume":"146","author":"Peyron","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2026041411311956500_bib7","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3324\/haematol.2024.286076","article-title":"A fully humanized von Willebrand disease type 1 mouse model as unique platform to investigate novel therapeutic options","volume":"110","author":"McCluskey","year":"2025","journal-title":"Haematologica"},{"issue":"13","key":"2026041411311956500_bib8","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1182\/blood.2024024055","article-title":"The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1","volume":"144","author":"Chion","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026041411311956500_bib9","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/jth.14471","article-title":"von Willebrand factor sialylation- a critical regulator of biological function","volume":"17","author":"Ward","year":"2019","journal-title":"J Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2549\/2513584\/blooda_adv-2026-019629-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2549\/2513584\/blooda_adv-2026-019629-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:31:26Z","timestamp":1776180686000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/7\/2549\/567696\/Monovalent-antibody-treatment-of-von-Willebrand"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019629","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,14]]},"published":{"date-parts":[[2026,4,14]]}}}